Form 8-K TG THERAPEUTICS, INC. For: Nov 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Roth Positive on TG Therapeutics (TGTX) Following Q3 Results; Expects Strong ASH Showing
November 11, 2014 11:31 AM ESTRoth Capital affirms TG Therapeutics (Nasdaq: TGTX) at Buy with a price target of $25 following Q3 results. TGTX posted Q3 loss of $0.51 per share, versus the firm's estimate looking for a loss of $0.32 per share.
Analyst Joseph Pantginis commented, Over the last 12 months, TG has transformed itself with what we consider to be striking clinical data to a pivotal stage company. The... More
